Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes

R. K. Burt*, W. R. Drobyski, A. E. Traynor, C. J. Link

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Patients with recurrent leukemia after an allogeneic hematopoietic stem cell transplant may be treated with donor lymphocyte infusions (DLI). The transfusion of lymphocytes from the original hematopoietic stem cell donor induces remission in approximately one third of relapsed AML cases and 80% of relapsed CML. DLI may be complicated by delayed and sometimes lethal graft-versus-host disease (GVHD). In an attempt to avoid this complication, several centers have initiated DLI trials in which the infused lymphocytes carry a suicide gene, herpes simplex thymidine kinase (HStk), which confers sensitivity to ganciclovir (GCV). In the event of severe GVHD, administration of GCV should terminate or ameliorate GVHD.

Original languageEnglish (US)
Pages (from-to)1043-1051
Number of pages9
JournalBone Marrow Transplantation
Issue number10
StatePublished - 1999


  • Donor lymphocyte infusions
  • Gene therapy
  • Retroviral vector

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes'. Together they form a unique fingerprint.

Cite this